Does Residual Muscular Weakness Lead to an Increase in Respiratory Complications in Bariatric Patients?

NACompletedINTERVENTIONAL
Enrollment

330

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

February 29, 2016

Study Completion Date

February 29, 2016

Conditions
Respiratory ComplicationMorbid Obesity
Interventions
DEVICE

Accelomyography

quantitative measurement of the train-of-four with the TOF Watch to determine timing of administration of neostigmine and extubation To assure patient flow the time to reversal administration will be limited to approximately 30 minutes after achieving 4 twitches in qualitative monitoring

DRUG

Neostigmine

Neostigmine is used to reverse the effects of neuromuscular blocking agents

DEVICE

Qualitative Monitor

Qualitative (tactile or visual) assessment of residual neuromuscular paralysis

Trial Locations (1)

32086

Flagler Hospital, Saint Augustine

All Listed Sponsors
lead

Coastal Anesthesiology Consultants

OTHER

NCT02037516 - Does Residual Muscular Weakness Lead to an Increase in Respiratory Complications in Bariatric Patients? | Biotech Hunter | Biotech Hunter